MedTrace Logo

CAR-NK Cells (CL-NK-003) in Pancreatic Cancer

NCT07425483 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-02-23

No results posted yet for this study

Summary

This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.

Conditions

Interventions

BIOLOGICAL

CL-NK-003

Fixed-dose (3 × 10\^9 cells)

Sponsors & Collaborators

  • National Key Laboratory of Immunity and Inflammation

    collaborator UNKNOWN

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhuan Liao · Changhai Hospital

  • Xuetao Cao · National Key Laboratory of Immunity & Inflammation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-12
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07425483 on ClinicalTrials.gov